News
Pfizer, Amgen will rake in billions during ‘golden age’ for biosimilars: Analyst
During Pfizer’s second-quarter earnings conference call last week, many analysts were so focused on the company’s potential future payoff from its COVID-19 vaccine effort that they may have overlooked one area of the business that’s paying off now: biosimilars.